MMRi36 Induces Cell Death in Lymphomas with Mutant p53
Author Information
Author(s): Lama Rati, Wu Wenjie, Mavis Cory K., Ruiz Federico M., Querol-García Javier, Martin Diana, Chemler Sherry R., Chandra Dhyan, Goodrich David W., Hernandez-Ilizaliturri Francisco J., Muñoz Inés G., Wang Xinjiang
Primary Institution: Roswell Park Comprehensive Cancer Center
Hypothesis
Can targeting MDM2/MDM4/XIAP with MMRi36 induce apoptosis in p53-mutant lymphomas?
Conclusion
MMRi36 effectively induces apoptosis in p53-mutant lymphoma cells by degrading MDM2, MDM4, and XIAP.
Supporting Evidence
- MMRi36 was identified as a potent apoptosis inducer in p53-mutant lymphoma cells.
- MMRi36 promotes degradation of MDM2, MDM4, and XIAP, leading to apoptosis.
- MMRi36 showed superior apoptotic responses compared to other chemotherapeutics in the study.
Takeaway
Researchers found a new drug, MMRi36, that helps kill cancer cells in lymphomas with a broken p53 gene by making certain proteins disappear.
Methodology
The study involved screening small molecules for their ability to induce apoptosis in p53-mutant lymphoma cells and assessing the effects on protein levels and activity.
Limitations
The in vivo efficacy of MMRi36 was limited despite strong in vitro results.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website